STEATOEPATITE (MASLD/MASH): LA TERAPIA. LINEA GUIDA AISF 2026. MIND THE “STEPS”! DA “DIGESTIVE AND LIVER DISEASE” (FREE).
AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update Associazione Italiana per lo Studio del Fegato (AISF) Abstract Metabolic dysfunction–associated steatotic liver disease (MASLD) has rapidly emerged as the leading cause of chronic liver disease worldwide, gradually replacing viral hepatitis in clinical and epidemiological relevance. Italian…

